- Home
- CNSP vs SNGX Comparison
CNSP vs SNGX Comparison
Compare CNSP & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNSP
- SNGX
- Stock Information
- Founded
- CNSP 2017
- SNGX 1987
- Country
- CNSP United States
- SNGX United States
- Employees
- CNSP N/A
- SNGX N/A
- Industry
- CNSP Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- CNSP Health Care
- SNGX Health Care
- Exchange
- CNSP Nasdaq
- SNGX Nasdaq
- Market Cap
- CNSP 5.6M
- SNGX 6.5M
- IPO Year
- CNSP 2019
- SNGX 1987
- Fundamental
- Price
- CNSP $8.82
- SNGX $1.32
- Analyst Decision
- CNSP Hold
- SNGX Strong Buy
- Analyst Count
- CNSP 1
- SNGX 1
- Target Price
- CNSP N/A
- SNGX $6.00
- AVG Volume (30 Days)
- CNSP 27.0K
- SNGX 2.7M
- Earning Date
- CNSP 08-13-2025
- SNGX 08-08-2025
- Dividend Yield
- CNSP N/A
- SNGX N/A
- EPS Growth
- CNSP N/A
- SNGX N/A
- EPS
- CNSP N/A
- SNGX N/A
- Revenue
- CNSP N/A
- SNGX $2,342.00
- Revenue This Year
- CNSP N/A
- SNGX N/A
- Revenue Next Year
- CNSP N/A
- SNGX N/A
- P/E Ratio
- CNSP N/A
- SNGX N/A
- Revenue Growth
- CNSP N/A
- SNGX N/A
- 52 Week Low
- CNSP $7.72
- SNGX $1.09
- 52 Week High
- CNSP $744.00
- SNGX $5.40
- Technical
- Relative Strength Index (RSI)
- CNSP 37.72
- SNGX 41.75
- Support Level
- CNSP $7.72
- SNGX $1.34
- Resistance Level
- CNSP $9.62
- SNGX $1.46
- Average True Range (ATR)
- CNSP 0.86
- SNGX 0.11
- MACD
- CNSP -0.13
- SNGX 0.03
- Stochastic Oscillator
- CNSP 29.99
- SNGX 62.16
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).